Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genoray Co (122310) Fair Value & Analysis

Healthcare · KR · Market cap 42.9B KRW

Price3,350 KRW
Fair Value3,320 KRW
Upside-0.9%
Quality94/100
Evidence: High Range 2,133 KRW – 4,339 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Genoray Co (122310) currently trades at 3,350 KRW, while our model-based Fair Value estimate is 3,320 KRW — implying the stock looks roughly 0.9% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It provides C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -56% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is Genoray Co (122310) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 3,320 KRW versus a price of 3,350 KRW — about −1% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 122310?
Our 21-model fair value for Genoray Co is 3,320 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 3,350 KRW.
What is the quality score of 122310?
Genoray Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.